Imaging Agent May Provide Early Info About Benefits of Hormone Therapies for Breast Cancer

Breast Cancer News (3/6) reports on a new study from the Journal of Nuclear Medicine which states that a new imaging agent that successfully measures changes in progesterone receptor (PR) levels may be used to determine if a breast cancer patient will respond to hormone therapies targeting the estrogen receptor (ER).

Print
Author: Nicole Hardy
0 Comments

Categories: 2019, March, News, Screening and MammographyNumber of views: 122

Tags: